Scilex Pharmaceutics, Inc. is suing Apotex Inc. over the Canadian drugmaker’s developing lidocaine patch, a generic challenger to Scilex’s ZTlido. Scilex says Apotex is violating three of ZTlido’s patents, centering around the patch’s non-aqueous lidocaine delivery. In the U.S., ZTlido is approved for the treatment of post-herpetic neuralgia, an indication for which it holds covered or better status for 57% of all insured lives under the pharmacy benefit. 10.6% of covered lives have preferred access to ZTlido without utilization management restrictions.
SOURCE: MMIT Analytics, as of 6/29/22